Union health minister J P Nadda on Friday said that Bharat Biotech initially did not mention ICMR and NIV as co-inventors in the patent application for Covaxin and the application was corrected after objections were raised by the government. Covaxin, which was widely used as a Covid vaccine, was jointly developed by the Indian Council of Medical Research (ICMR), National Institute of Virology, and Bharat Biotech International Ltd. nnRead more at: nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bharat-biotech-credited-icmr-niv-as-covaxin-co-inventors-after-missing-them-initially-government/articleshow/112219706.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
HYDERABAD, July 6 (Reuters) - India's pharmaceutical companies are hoping for tax incentives and financial assistance for research on innovative drugs as Prime Minister Narendra Modi's government readies a federal finance budget likely to be presented in July.
A study found that Bharat Biotech's Rotavac vaccine used in the government's immunization program increases the risk of intussusception in infants, a condition where the intestine telescopes into itself, leading to potential serious consequences.
Nearly a third of the participants of an observational study on the side-effects of Bharat Biotech's Covid-19 vaccine Covaxin reported adverse events of special interest (AESI), according to a report on SpringerLink, an integrated platform for journals and other materials published by Springer. Researchers found that female adolescents and those with a history of allergy are at a higher risk of AESI after receiving Covaxin, as per the report.
Bharat Biotech on Tuesday said it has collaborated with the Netherlands-based Bilthoven Biologicals B.V, a wholly-owned arm of Serum Institute of India, to strengthen production and supply security of oral polio vaccines. An agreement has been signed between the two partners under which Bharat Biotech will procure drug substances for the production of oral polio vaccines (OPVs) to be supplied within India and globally, the company said in a statement.
Bharat Biotech International Ltd on Sunday said it started clinical trials of the Tuberculosis vaccine Mtbvac on adults in India. This is the first vaccine against Tuberculosis derived from a human source by the Spanish biopharmaceutical company, Biofabri, a press release from Bharat Biotech said.
Bharat Biotech signs MoU with University of Sydney to collaborate on vaccine research
Bharat Biotech picks up 20 per cent stake in Eastman Exports Global Clothing
Singapore's sovereign fund Temasek Holdings is in advanced talks to acquire a minority stake of 15-20% in Cloudnine, a chain of women, childcare & fertility hospitals, said two people aware of the development. Temasek is likely to invest about ?500 crore, valuing the Bengaluru-based hospital chain at ?3,000 crore.
Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday. He was speaking on the sidelines of an event here at which a bilateral agreement was signed between the University of Wisconsin (UW)-Madison Global Health Institute (GHI) and the Ella Foundation for the establishment of the first-ever UW-Madison One Health Centre in Bengaluru.